You just read:

Salix Pharmaceuticals Announces the Publication of a Study Evaluating the Safety and Efficacy of UCERIS® (budesonide) Tablets for Induction of Remission in Patients with Active Mild to Moderate Ulcerative Colitis Refractory to Mesalamine Therapy

News provided by

Salix Pharmaceuticals, Ltd.

May 18, 2017, 08:13 ET